No Data
JW THERAP-B (02126) grants Juno a non-exclusive license for the JW sLVV production process and related technical knowledge.
JW THERAP-B (02126) announced that the company has reached an agreement with one of its major shareholders and related parties, Juno, regarding ...
Express News | JW (Cayman) Therapeutics - Grants Juno Therapeutics Non-Exclusive License Under Jw Slvv Manufacturing Process, Others
Positive Sentiment Still Eludes JW (Cayman) Therapeutics Co. Ltd (HKG:2126) Following 34% Share Price Slump
JW THERAP-B (02126) is issuing 0.4881 million shares according to the stock plan.
JW THERAP-B (02126) issued an announcement that on March 21, 2025, the company will issue based on the share plan...
JW THERAP-B (02126) released its annual performance, with an income of 0.158 billion yuan. It is expected that the sales revenue of Benod will increase again in the next period.
JW THERAP-B (02126) announced its annual performance for the year ending December 31, 2024, with the group achieving revenue...
Express News | JW (Cayman) Therapeutics FY Revenue RMB 158.2 Million
